X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13664) 13664
Book Review (2418) 2418
Publication (1211) 1211
Conference Proceeding (123) 123
Book Chapter (106) 106
Magazine Article (42) 42
Newspaper Article (27) 27
Dissertation (25) 25
Government Document (6) 6
Web Resource (6) 6
Book / eBook (5) 5
Trade Publication Article (5) 5
Reference (4) 4
Data Set (1) 1
Presentation (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (11368) 11368
index medicus (9677) 9677
humans (9325) 9325
female (7062) 7062
oncology (6738) 6738
breast cancer (5674) 5674
breast neoplasms - drug therapy (4667) 4667
cancer (3331) 3331
chemotherapy (3285) 3285
breast neoplasms - pathology (3081) 3081
antibodies, monoclonal, humanized (2942) 2942
middle aged (2890) 2890
receptor, erbb-2 - metabolism (2705) 2705
her2 (2501) 2501
antineoplastic agents - therapeutic use (2477) 2477
adult (2300) 2300
aged (2287) 2287
therapy (2178) 2178
breast neoplasms - metabolism (1980) 1980
animals (1879) 1879
antineoplastic combined chemotherapy protocols - therapeutic use (1851) 1851
antibodies, monoclonal - therapeutic use (1781) 1781
treatment outcome (1560) 1560
cell line, tumor (1559) 1559
breast neoplasms - genetics (1533) 1533
care and treatment (1484) 1484
adjuvant chemotherapy (1438) 1438
receptor, erbb-2 - genetics (1431) 1431
metastasis (1386) 1386
prognosis (1384) 1384
survival (1369) 1369
monoclonal-antibody (1359) 1359
skin and connective tissue diseases (1291) 1291
breast-cancer (1280) 1280
research (1203) 1203
mice (1201) 1201
expression (1182) 1182
medicine & public health (1166) 1166
tumors (1164) 1164
immunohistochemistry (1108) 1108
epidermal growth factor (1077) 1077
analysis (1062) 1062
receptor, erbb-2 - antagonists & inhibitors (1048) 1048
antineoplastic agents - pharmacology (1035) 1035
erbb-2 protein (1013) 1013
pharmacology & pharmacy (975) 975
lapatinib (973) 973
cancer therapies (928) 928
metastatic breast-cancer (888) 888
antibodies, monoclonal - administration & dosage (886) 886
drug therapy (882) 882
disease-free survival (873) 873
male (869) 869
antibodies, monoclonal, humanized - therapeutic use (862) 862
aged, 80 and over (858) 858
health aspects (849) 849
neoplasm staging (821) 821
antineoplastic agents - adverse effects (818) 818
paclitaxel (816) 816
breast neoplasms - mortality (814) 814
chemotherapy, adjuvant (814) 814
gene amplification (805) 805
docetaxel (785) 785
receptor, erbb-2 - analysis (750) 750
trial (750) 750
antibodies, monoclonal, humanized - administration & dosage (738) 738
monoclonal antibodies (735) 735
antineoplastic agents (731) 731
resistance (727) 727
efficacy (723) 723
neoplasm metastasis (709) 709
retrospective studies (708) 708
growth-factor receptor (705) 705
carcinoma (704) 704
antibodies, monoclonal - pharmacology (703) 703
open-label (702) 702
receptor (698) 698
neoplasms (696) 696
phase-ii (696) 696
neoadjuvant therapy (693) 693
hematology, oncology and palliative medicine (686) 686
cardiotoxicity (665) 665
patients (665) 665
pertuzumab (663) 663
antineoplastic agents - administration & dosage (657) 657
article (653) 653
antimitotic agents (650) 650
breast neoplasms - therapy (625) 625
clinical trials (620) 620
cell biology (618) 618
herceptin (617) 617
trastuzumab resistance (617) 617
amplification (607) 607
proteins (600) 600
gene expression (588) 588
women (586) 586
receptor, erbb-2 - immunology (574) 574
cells (573) 573
pathology (573) 573
surgery (561) 561
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12811) 12811
French (294) 294
Japanese (266) 266
German (162) 162
Chinese (89) 89
Spanish (53) 53
Polish (36) 36
Italian (27) 27
Russian (26) 26
Portuguese (21) 21
Hungarian (18) 18
Korean (17) 17
Czech (16) 16
Turkish (10) 10
Dutch (7) 7
Danish (5) 5
Finnish (5) 5
Hebrew (4) 4
Swedish (4) 4
Norwegian (3) 3
Slovak (3) 3
Slovenian (3) 3
Serbian (2) 2
Bosnian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A874
Journal Article
Journal of Japanese Society of Gastroenterology, ISSN 0446-6586, 2017, Volume 114, Issue 1, pp. 59 - 68
Journal Article
WHO Drug Information, ISSN 1010-9609, 04/2018, Volume 32, Issue 2, pp. 217 - 217
Journal Article
WHO Drug Information, ISSN 1010-9609, 01/2018, Volume 32, Issue 1, pp. 36 - 36
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Summary Background Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall... 
Internal Medicine | SYSTEM | MEDICINE, GENERAL & INTERNAL | MULTICENTER | PHASE-3 TRIAL | OPEN-LABEL | RANDOMIZED CONTROLLED-TRIAL | PERTUZUMAB | Antineoplastic Agents, Immunological - administration & dosage | Trastuzumab - therapeutic use | Drug Administration Schedule | Follow-Up Studies | Biomarkers, Tumor - analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Breast Neoplasms - chemistry | Antineoplastic Agents, Immunological - therapeutic use | Breast Neoplasms - pathology | Chemotherapy, Adjuvant - methods | Adult | Female | Aged | Receptor, ErbB-2 - analysis | Heart Diseases - chemically induced | Antimitotic agents | Medical colleges | Analysis | Adjuvant treatment | Monoclonal antibodies | Breast cancer | Antineoplastic agents | Cancer | Heart | Laboratories | Toxicity | Medical services | Clinical trials | Cancer therapies | Incidence | Motivation | Failure analysis | Surgery | Heart diseases | Recombinant | Medical research | Health risks | Mammography | Radiation therapy | Patients | Survival | ErbB-2 protein | Chemotherapy | Breast | Informed consent | Trastuzumab | Schedules | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 08/2019, Volume 37, Issue 23, pp. 2092 - 2092
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 05/2019, Volume 25, Issue 10, pp. 2949 - 2955
On December 20, 2017, the FDA granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients... 
TRASTUZUMAB | ONCOLOGY | PACLITAXEL
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 2019, Volume 14, Issue 5, pp. e0217716 - e0217716
[This corrects the article DOI: 10.1371/journal.pone.0216095.]. 
Pertuzumab | ErbB-2 protein | Trastuzumab
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 12/2016, Volume 33, Issue 12, pp. 2930 - 2942
The ability of human melanotransferrin (hMTf) to carry a therapeutic concentration of trastuzumab (BTA) in the brain after conjugation (in the form of... 
Biochemistry, general | Biomedical Engineering | human melanotransferrin (hMTf) | trastuzumab (BTA) | Biomedicine | antibody trastuzumab-melanotransferrin conjugate (BT2111) | Pharmacy | blood brain barrier (BBB) | brain metastases | Medical Law | metastatic HER2+ breast cancer tumors | Pharmacology/Toxicology | SURVIVAL | BARRIER | IRON | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | HER2-POSITIVE BREAST-CANCER | P97 | metastatic HER2+breast cancer tumors | TRANSFERRIN RECEPTOR | TRANSCYTOSIS | PHARMACOLOGY & PHARMACY | EMTANSINE T-DM1 | CEREBRAL-BLOOD-FLOW | Optical Imaging | Trastuzumab - pharmacokinetics | Humans | Membrane Glycoproteins - chemistry | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - administration & dosage | Brain - metabolism | Brain Neoplasms - secondary | Heterografts | Female | Antineoplastic Agents - pharmacokinetics | Trastuzumab - chemistry | Fluorescent Dyes - chemistry | Trastuzumab - administration & dosage | Permeability | Antineoplastic Agents - chemistry | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Blood-Brain Barrier - metabolism | Brain - drug effects | Animals | Breast Neoplasms - pathology | Mice, Nude | Brain - pathology | Cell Line, Tumor | Protein Binding | Brain | Care and treatment | Brain tumors | Analysis | Oncology, Experimental | Breast cancer | Metastasis | Research | Cancer | Drug therapy | Index Medicus | Brain Metastases | Human melanotransferrin (hMTf) | Trastuzumab (BTA) | Antibody trastuzumab-melanotransferrin conjugate (BT2111) metastatic HER2+ breast cancer tumors | Blood Brain Barrier (BBB)
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2019, Volume 30, Issue 1, pp. 147 - 147
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 2, pp. 122 - 131
Journal Article